Canadian Cancer Trials Group - Tumour Bank
Logged in as: Public
Location: Home - Disease Sites - - MA27
MA27 Details
Status: Closed 
Activation Date: 2003JUN02
Closing Date: 2008JUL31
Phase: III 

Description: A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer 

Eligibility: Post-menopausal women who have histologically or cytologically confirmed, receptor-positive, adequately excised, primary breast cancer are eligible for this trial. Adjuvant chemotherapy and radiation are allowable. Chemotherapy must be completed before randomization. Radiotherapy may be given prior to or concurrently with protocol therapy. 

Objective: To compare event free survival (EFS) between women treated with Exemestane or Anastrozole as adjuvant therapy. To compare the incidence of contralateral breast cancer, the time to distant recurrence, survival & safety among treatment groups. 

Participation: NCIC CTG, CTSU sites, IBCSG 

Lay Description: The purpose of this study is to compare the ability of Exemestane and Anasrozole to prevent the recurrence of breast cancer and to compare their side effects. Every patient will receive one of these two drugs. This research is being done because there is still a risk of breast cancer returning after surgery. While current chemotherapy and hormone therapy (eg Tamoxifen) are useful, we want to improve the chance that the cancer will not return and we do not know which of the drugs is better. 

Primary Publication Show

Other Publications Show

Hide Tissue Samples
Disease Site Trial Code Patients Accrued Patients - Blocks Patients - Slides Patients - Blocks and/or Slides
BREAST MA27 7576 3920 4029 4354
Hide TMA Samples
(Core size is 0.6 mm)
Disease Site Trial Code Patients Accrued TMA Blocks Patients on TMA Blocks
BREAST MA27 7576 79 3610
Hide Fluid Samples
Disease Site Trial Code Patients Accrued Patients - Whole Blood Patients - Cellular Component of Blood Patients - DNA extracted from Blood Patients - RNA extracted from Blood Patients - Plasma Patients - Serum Patients - Urine Patients - Buccal
BREAST MA27 7576 3281 0 4575 0 3554 4 0 0